MAW and SJ are employees of AstraZeneca R&D, Mölndal, Sweden (AstraZeneca manufacture rosuvastatin). LAGR and EMG are employed by CEIFE, which has received research grants from AstraZeneca.
Article first published online: 21 APR 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 17, Issue 10, pages 943–952, October 2008
How to Cite
García-Rodríguez, L. A., Massó-González, E. L., Wallander, M.-A. and Johansson, S. (2008), The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidem. Drug Safe., 17: 943–952. doi: 10.1002/pds.1603
This study is based in part on data from the Full Feature General Practice Research Database obtained under licence from the UK Medicines and Healthcare Products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone.
- Issue published online: 24 SEP 2008
- Article first published online: 21 APR 2008
- Manuscript Accepted: 9 MAR 2008
- Manuscript Received: 29 FEB 2008
To compare mortality and the incidence of hospitalization for myopathy, rhabdomyolysis, acute renal failure and acute liver injury in patients receiving rosuvastatin and those taking other statins.
Patients prescribed a statin that they had not used before were selected from the UK General Practice Research Database (GPRD) and followed up from 1 April 2003 to 31 December 2005.
We studied 10 289 patients on rosuvastatin and 117 102 taking other statins. No cases of myopathy, rhabdomyolysis or acute liver injury occurred among rosuvastatin users. In those taking statins other than rosuvastatin, the incidence of myopathy was 0.4 (95% confidence interval (CI): 0.1–0.9), of rhabdomyolysis was 0.4 (95%CI: 0.1–0.9) and of acute liver injury was 0.4 (95%CI: 0.2–1.0), per 10 000 person-years. Fourteen cases of acute renal failure were identified (two among rosuvastatin users and 12 among other statin users). Among current users, the relative risk (RR) of acute renal failure in rosuvastatin users compared with other statin users was 1.16 (95%CI: 0.15–9.03).
We identified 3232 deaths during the study period (173 in the rosuvastatin-treated group and 3059 in the other statin group). The RR of death associated with current use of rosuvastatin compared with other statins was 0.55 (95%CI: 0.44–0.68).
We found no evidence that patients prescribed rosuvastatin were at greater risk of these outcomes than patients prescribed other statins. There was no evidence of increased mortality among patients taking rosuvastatin, even after allowing for age, sex and prior statin use. Copyright © 2008 John Wiley & Sons, Ltd.